blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3189050

EP3189050 - ANTIVIRAL AGENTS AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.12.2020
Database last updated on 13.07.2024
FormerThe patent has been granted
Status updated on  03.01.2020
FormerGrant of patent is intended
Status updated on  09.09.2019
FormerExamination is in progress
Status updated on  09.11.2018
FormerRequest for examination was made
Status updated on  15.06.2017
FormerThe international publication has been made
Status updated on  01.04.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): AL, MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Griffith University
170 Kessels Road
Nathan, Queensland 4111 / AU
[2017/28]
Inventor(s)01 / VON ITZSTEIN, Mark
2/68 Tallebudgera Drive
Palm Beach, Queensland 4221 / AU
02 / EL-DEEB, Ibrahim
508/33 Clark Street
Biggera Waters, Queensland 4216 / AU
03 / DIRR, Larissa
232/1 Serisier Avenue
Main Beach, Queensland 4217 / AU
04 / GUILLON, Patrice
32808/9 Lawson Street
Southport, Queensland 4215 / AU
05 / WINGER, Moritz
4/ 8 Mary Avenue
Broadbeach, Queensland 4218 / AU
 [2017/28]
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2020/06]
Former [2017/28]Schiweck, Weinzierl & Koch Patentanwälte Partnerschaft mbB
Landsberger Straße 98
80339 München / DE
Application number, filing date15837720.007.09.2015
[2017/28]
WO2015AU50526
Priority number, dateNL2014201342005.09.2014         Original published format: NL 2013420
[2017/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016033660
Date:10.03.2016
Language:EN
[2016/10]
Type: A1 Application with search report 
No.:EP3189050
Date:12.07.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 10.03.2016 takes the place of the publication of the European patent application.
[2017/28]
Type: B1 Patent specification 
No.:EP3189050
Date:05.02.2020
Language:EN
[2020/06]
Search report(s)International search report - published on:AU10.03.2016
(Supplementary) European search report - dispatched on:EP25.01.2018
ClassificationIPC:A61K31/351, A61K31/36, A61K31/4025, A61K31/403, A61K31/41, A61K31/4192, C07D405/14, C07D309/28, C07D405/04, C07D407/12, C07D309/08, A61P31/14, A61P31/16
[2018/09]
CPC:
A61K31/4192 (EP,KR,RU,US); C07D405/04 (EP,KR,RU,US); A61K31/351 (EP,KR,US);
A61K31/36 (EP,KR,US); A61K31/4025 (EP,KR,US); A61K31/403 (EP,US);
A61K31/4035 (RU); A61K31/41 (EP,RU,US); A61P31/12 (EP,RU);
A61P31/14 (EP); A61P31/16 (EP,RU); A61K2300/00 (US) (-)
Former IPC [2017/28]C07D405/04, A61K31/4192, A61K31/4035, A61K31/41, A61P31/12, A61P31/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/28]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:ANTIVIRALE WIRKSTOFFE UND VERWENDUNGEN DAVON[2017/28]
English:ANTIVIRAL AGENTS AND USES THEREOF[2017/28]
French:AGENTS ANTIVIRAUX ET LEURS UTILISATIONS[2017/28]
Entry into regional phase31.03.2017National basic fee paid 
31.03.2017Search fee paid 
31.03.2017Designation fee(s) paid 
31.03.2017Examination fee paid 
Examination procedure31.03.2017Examination requested  [2017/28]
31.03.2017Date on which the examining division has become responsible
27.07.2018Amendment by applicant (claims and/or description)
12.11.2018Despatch of a communication from the examining division (Time limit: M04)
19.03.2019Reply to a communication from the examining division
07.06.2019Despatch of a communication from the examining division (Time limit: M02)
12.08.2019Reply to a communication from the examining division
10.09.2019Communication of intention to grant the patent
21.11.2019Receipt of the translation of the claim(s)
31.12.2019Fee for grant paid
31.12.2019Fee for publishing/printing paid
Opposition(s)06.11.2020No opposition filed within time limit [2021/02]
Fees paidRenewal fee
08.09.2017Renewal fee patent year 03
21.09.2018Renewal fee patent year 04
13.09.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL05.02.2020
CY05.02.2020
EE05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MK05.02.2020
MT05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
LU07.09.2020
[2022/31]
Former [2022/28]CY05.02.2020
EE05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MT05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
LU07.09.2020
Former [2021/27]EE05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
LU07.09.2020
Former [2021/23]EE05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2021/13]EE05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/50]EE05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
RO05.02.2020
RS05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/49]HR05.02.2020
LT05.02.2020
LV05.02.2020
RO05.02.2020
RS05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/48]HR05.02.2020
LT05.02.2020
LV05.02.2020
RO05.02.2020
RS05.02.2020
SM05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/47]HR05.02.2020
LT05.02.2020
LV05.02.2020
RS05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/40]HR05.02.2020
LV05.02.2020
RS05.02.2020
BG05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/39]HR05.02.2020
LV05.02.2020
RS05.02.2020
BG05.05.2020
GR06.05.2020
PT28.06.2020
Former [2020/38]HR05.02.2020
LV05.02.2020
RS05.02.2020
GR06.05.2020
PT28.06.2020
Former [2020/37]HR05.02.2020
LV05.02.2020
RS05.02.2020
PT28.06.2020
Former [2020/36]RS05.02.2020
PT28.06.2020
Documents cited:Search[ID]WO02076971  (BIOCRYST PHARM INC [US], et al) [ID] 1-15 * page 1, lines 6-11 * * page 52; example 26 * * page 63, lines 4-16 * * claims 6, 10 *;
 [A]WO2011006237  (UNIV BRITISH COLUMBIA [CA], et al) [A] 1-15 * pages 25-26; compound C4Bn * * claims 1, 24, 26, 30, 42 *;
 [X]  - LI J ET AL, "Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 19, ISSN 0960-894X, (20061001), pages 5009 - 5013, (20061001), XP027966575 [X] 1-15 * abstract * * table 1 * * page 5012, column 2, paragraph 1 *
 [XI]  - FENG ENGUANG ET AL, "Recent Advances in Neuraminidase Inhibitor Development as Anti-influenza Drugs", CHEMMEDCHEM, (201209), vol. 7, no. 9, ISSN 1860-7179, pages 1527 - 1536, XP002738547 [X] 1-3,6-8,11-15 * abstract * * page 1529, column 2, paragraph l - page 1530, column 1, paragraph 1 * * figure 6 * [I] 4,5,9,10

DOI:   http://dx.doi.org/10.1002/cmdc.201200155
 [X]  - LU ET AL, "Synthesis of C-4 and C-7 triazole analogs of zanamivir as multivalent sialic acid containing scaffolds", CARBOHYDRATE RESEARCH, PERGAMON, GB, (20070716), vol. 342, no. 12-13, doi:10.1016/J.CARRES.2007.06.002, ISSN 0008-6215, pages 1636 - 1650, XP022155719 [X] 1-3,5-8,10 * figure 1; compound 2 * * figure scheme 1 * * page 1640; table 1 *

DOI:   http://dx.doi.org/10.1016/j.carres.2007.06.002
 [A]  - YE DEJU ET AL, "Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (2012), vol. 54, doi:10.1016/J.EJMECH.2012.06.033, ISSN 0223-5234, pages 764 - 770, XP028932621 [A] 1-15 * abstract * * table 1 * * page 767, column 1, paragraph l - column 2, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2012.06.033
 [A]  - I. V. ALYMOVA ET AL, "Efficacy of Novel Hemagglutinin-Neuraminidase Inhibitors BCX 2798 and BCX 2855 against Human Parainfluenza Viruses In Vitro and In Vivo", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20040422), vol. 48, no. 5, doi:10.1128/AAC.48.5.1495-1502.2004, ISSN 0066-4804, pages 1495 - 1502, XP055182866 [A] 1-15 * abstract * * page 1496, column 1, paragraph 3 * * figure 1 *

DOI:   http://dx.doi.org/10.1128/AAC.48.5.1495-1502.2004
 [A]  - TINDAL ET AL, "Synthesis and evaluation of 4-O-alkylated 2-deoxy-2,3-didehydro-N-acetylneuraminic acid derivatives as inhibitors of human parainfluenza virus type-3 sialidase activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (20070220), vol. 17, no. 6, doi:10.1016/J.BMCL.2006.12.105, ISSN 0960-894X, pages 1655 - 1658, XP005895383 [A] 1-15 * abstract * * page 1656, column 2, paragraph l - page 1657, column 2, paragraph 1 * * table 1 *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2006.12.105
 [XDP]  - PATRICE GUILLON ET AL, "Structure-guided discovery of potent and dual-acting human parainfluenza virus haemagglutinin-neuraminidase inhibitors", NATURE COMMUNICATIONS, (20141020), vol. 5, doi:10.1038/ncomms6268, page 5268, XP055440108 [XDP] 1-15 * abstract * * figures 1, 4, 5 * * page 7, column 1, paragraph 1 - page 8, column 1, paragraph 3 *

DOI:   http://dx.doi.org/10.1038/ncomms6268
International search[X]WO02076971  (BIOCRYST PHARM INC [US], et al) [X] 1-19 * see page 1 lines 7-11 and lines 15-19; page 3 lines 19-26; page 13 lines 1-2; page 19 scheme 1; claim 9 page 77 lines 15-16 and page 81 lines 9-10; page 51 compound 12; page 52 compound 26; page 63 lines 9-16 and lines 4-5; claims 6-8 *;
 [X]  - LI, J. et al., "Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities", Bioorganic & Medicinal Chemistry Letters, (20060000), vol. 16, no. 19, doi:doi:10.1016/j.bmcl.2006.07.047, pages 5009 - 5013, XP027966575 [X] 1-15 and 17-19 * . see abstract; page 5009 left column lines 1-12; compounds 3a and 3f-k in table 1 on page 5010; page 5011 left column lines 6-12. *
 [X]  - LU, Y. et al., "Synthesis of C-4 and C-7 triazole analogs of zanamivir as multivalent sialic acid containing scaffolds", Carbohydrate Research, (20070000), vol. 342, no. 12-13, doi:doi:10.1016/j.carres.2007.06.002, pages 1636 - 1650, XP029074260 [X] 1-3 and 5-10 * . see compound 8 on page 1640 table 1 and pages 1641-1642; compound 9 on page 1640 table 1 and pages 1642-1643; compound 17 page 1646; compound 18 page 1646. *

DOI:   http://dx.doi.org/10.1016/j.carres.2007.06.002
 [A]  - SHIDMOOSSAVEE, F. S. et al., "Chemical Insight into the Emergence of Influenza Virus Strains that are Resistant to Relenza", Journal of the American Chemical Society, (20130000), vol. 135, no. 36, doi:doi:10.1021/ja405916q, pages 13254 - 13257, XP 055182952 [A] 1-15 and 17-19 * . see compound 2c page 13255 figure 1; page 13254 and page 13255 figure 1. *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.